USPTO serial 79381492
PLEQSTIBA
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Dec 3, 2024
- Examiner
- PARKS, KIMBERLY L
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with PLEQSTIBA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Scott D. Woldow
Scott D. Woldow SMITH, GAMBRELL & RUSSELL, LLP1055 THOMAS JEFFERSON ST. NW, SUITE 400WASHINGTON, DC 20007United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations for cardiovascular diseases, illnesses, and conditions; Pharmaceutical preparations for infusion conditions; pharmaceutical preparations for cardiovascular conditions and blood conditions, namely, novel, plasma derived apolipoprotein A-I conditions while undergoing infusion therapy; pharmaceutical preparations for novel apolipoprotein A-I infusion therapy to potentially reduce the risk of recurrent major adverse cardiovascular events (MACE) in patients within 90 days of an acute myocardial infarction (AMI) with a sustained benefit for 365 days; Pharmaceutical preparations for acute myocardial infarction (AMI); Pharmaceutical preparations for cardiovascular diseases; pharmaceutical preparations for treating von Willebrand disease, hemophilia, primary immunodeficiency, hereditary angioedema, fibrinogen deficiency, Alpha 1 antitrypsin deficiency, and inflammatory demyelinating polyneuropathy; Pharmaceutical preparations for the treatment and prevention of blood and bleeding disorders; pharmaceutical preparations for the treatment of hemophilia; pharmaceutical products derived from recombinant DNA technology for the treatment of hemophilia, namely, pharmaceutical preparations derived from recombinant DNA technology for the treatment of hemophilia; pharmaceutical preparations and substances for the treatment of blood disorders; pharmaceutical preparations for the treatment of blood conditions, respiratory conditions, pneumonia, covid-19, and influenza; Pharmaceutical preparations, namely, antibody for the treatment of acute respiratory distress syndrome, ARDS; pharmaceutical preparations, namely, antibody for the treatment of Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD; Pharmaceutical preparations, namely, antibody for the treatment of Hereditary Angioedema, HAE; Pharmaceutical preparations, namely, for the treatment of Hereditary Angioedema, HAE, respiratory diseases, acute respiratory distress syndrome, ARDS, Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| May 24, 2025 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| May 6, 2025 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| May 6, 2025 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Apr 4, 2025 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Mar 18, 2025 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Mar 18, 2025 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Mar 3, 2025 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Dec 3, 2024 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Dec 3, 2024 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Oct 1, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Oct 1, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Sep 11, 2024 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Aug 27, 2024 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Aug 27, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Aug 27, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 27, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 3, 2024 | RFNP | REFUSAL PROCESSED BY IB | — |
| May 16, 2024 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| May 16, 2024 | RFRR | REFUSAL PROCESSED BY MPU | — |
| May 7, 2024 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| May 6, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 30, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Feb 16, 2024 | PARI | TEAS VOLUNTARY AMENDMENT RECEIVED | — |
| Oct 24, 2023 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Oct 20, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Oct 19, 2023 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |